| Budget Amount *help |
¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2022: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2021: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2020: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2019: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2018: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
|
|---|
| Outline of Final Research Achievements |
There is a periostin splicing variant that exerts a cardioprotective effect on exosome expression in the heart when myocardial stem cells secrete exosomes. As a result, it was confirmed that the cardiomyocyte proliferation effect was observed, and as a result, the deterioration of cardiac function with AMI was suppressed.
In a rhabdomyolytic renal failure model with intramuscular injection of 50% glycerol, we confirmed that inhibition of a specific periostin variant exerts a reno-protective effect.
Injecting the abnormal splicing gene of clinical cardiomyopathy, we confirmed that inhibition of periostin has a cardio-protective effect on a mouse model of cardiomyopathy.
|
